FDA Releases Draft Guidance on Residual Drug in Transdermal and Related Drug Delivery Systems

Summary

The Food and Drug Administration (FDA) has made available a draft guidance document for the pharmaceutical industry, outlining recommendations for minimizing residual drug substance in transdermal and related drug delivery systems, such as transmucosal and topical patch products, during product design, development, and manufacturing.